Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is under phase 3 development by GSK to treat anemia associated with chronic kidney disease (CKD). Inhibition of
Daurismo is claimed to be the first and only FDA-approved Hedgehog pathway inhibitor for AML. Daurismo, which is taken in combination with low-dose cytarabine (LDAC), has not been
The research collaboration brings together Evotec’s leading induced pluripotent stem cell (iPSC) platform and broad drug discovery capabilities with Immuneering’s unique artificial intelligence-driven drug discovery platform to accelerate
In October 2017, the FDA granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for Aemcolo. With the QDIP designation, intended for antibacterial drugs that treat serious
The companies reported that the trial assessing avelumab alone or in combination with PLD has not achieved the pre-specified primary endpoints of OS or PFS compared with PLD
Promacta, which is marketed as Revolade in most countries outside the US, is an oral thrombopoietin receptor agonist (TPO-RA) that is already approved for SAA for patients who
The company has reported the final OS results for the phase III Mystic trial, which is a study of Imfinzi monotherapy and the combination of Imfinzi and anti-CTLA4
Nexus Pharmaceuticals chief commercial officer Omair Ahmed said: “The approval of generic Arsenic Trioxide injection continues to show Nexus’s commitment in providing access to affordable critical-need generic injectables.
As part of the collaboration worth $300m, Boehringer and Epizyme will involve in the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed
SEA-BCMA is an investigational antibody empowered using Seattle Genetics’ proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody dependent cellular cytotoxicity. The target of SEA-BCMA, the cell
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.